You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

275 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gemcitabine,
CISplatin,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gemcitabine,
CISplatin,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
fluorouracil,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Neoadjuvant
Drugs Used:
fluorouracil,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
fludarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
fludarabine,
cyclophosphamide,
mitoXANTRONE,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
fludarabine,
cyclophosphamide,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
irinotecan,
leucovorin,
fluorouracil,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet (FOLFIRI), Patient Info Sheet (FOLFIRI+BEVA)
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
fludarabine (Unfunded),
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
fludarabine,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2018
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020

Pages